Stem cell therapies are beginning to enter the clinic, and with the clinical phases of development being highly regulated, there is a requirement for cGMP (Current Good Manufacturing Practice) ancillary reagents (raw materials) to assure therapy safety and suitability. At Tocris we support this development from the research to clinical phase, by offering the first cGMP small molecules for stem cell therapy. Partner with Tocris today and let us, help you develop the next stem cell therapy.
To view Bio-Techne's complete solutions for Cell and Gene Therapy manufacturing, including all GMP-grade reagents and analytical instrumentation, please visit bio-techne.com.
Stay in Touch and enim ad veniam quis nostrud exercitation ullamco